INDIRECT TREATMENT COMPARISON OF USTEKINUMAB VERSUS OTHER BIOLOGICS IN MODERATE-TO-SEVERE CROHN'S DISEASE PATIENTS HAVING FAILED ANTI-TNF THERAPY ‒ A 1-YEAR TREATMENT SEQUENCE ANALYSIS INCLUDING DELAYED RESPONDERS

Laura Mesana  1     Maud Pacou  2     Dominik Naessens  3     Sheldon Sloan  4     Aline Gauthier  1    
1 Amaris,London,United Kingdom
2 Amaris,Paris,France
3 Janssen Pharmaceutica,Beerse,Belgium
4 Janssen Global Services,Horsham,United States of America

Conference
25th UEG Week 2017

Citation
United European Gastroenterology Journal 2017; 5 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing